Reimbursement and Market Access for Drugs in Japan

Obtain a high drug reimbursement price from Japan’s Chuikyo.

To learn more about Japan drug reimbursement, please contact us.

Japan is a large drug market, but similar to the US and EU, it is trying to reduce spending on drugs. Health technology assessments will be the key driver for new and likely expensive drug products. While drug prices were adjusted every 2 years in the past, over the last few years, annual price adjustments have been made.

After drug approval, drug manufacturers need to get pricing in Japan’s National Health Insurance Scheme. The MHLW‘s Central Social Insurance Medical Council (Chuikyo) determines the starting reimbursement price using a comparable price scheme. For new drugs pricing is determined by a cost method. To encourage innovative drugs, the MHLW allows increased prices awards (premiums) via a number of different scenarios. Innovative drugs are drugs that are more beneficial than existing drugs, including new orphan or paediatric products. Similarly, drugs with less benefit over time face price reductions.

To learn more about Japan drug reimbursement, please contact us.

Related Resources

Visit our Resource Center to view free webcasts and charts or read publications, news, and research reports on the Asia medical markets.

Related News Briefs

Visit our Resource Center to view free webcasts and charts or read publications, news, and research reports on the Asia medical markets.